Estrogen-Receptor Negative Breast Cancer disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: EST002 MIFTS: 44	Estrogen-Receptor Negative Breast Cancer Categories: Cancer diseases
Genes Tissues Related diseases Publications Pathways Drugs Download Expand all tables

Sources

Aliases & Classifications for Estrogen-Receptor Negative Breast Cancer

MalaCards integrated aliases for Estrogen-Receptor Negative Breast Cancer:

Name: Estrogen-Receptor Negative Breast Cancer ¹² ¹⁵

Classifications:

MalaCards categories:
Global: Cancer diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹² DOID:0060076

Sources

Summaries for Estrogen-Receptor Negative Breast Cancer

MalaCards based summary : Estrogen-Receptor Negative Breast Cancer is related to estrogen-receptor positive breast cancer and breast cancer. An important gene associated with Estrogen-Receptor Negative Breast Cancer is ESR1 (Estrogen Receptor 1), and among its related pathways/superpathways are Glioma and Gastric cancer. The drugs Bevacizumab and Cyclophosphamide have been mentioned in the context of this disorder. Affiliated tissues include breast, brain and lymph node, and related phenotypes are growth/size/body region and endocrine/exocrine gland

Sources

Related Diseases for Estrogen-Receptor Negative Breast Cancer

Diseases in the Estrogen-Receptor Positive Breast Cancer family:

Estrogen-Receptor Negative Breast Cancer

Diseases related to Estrogen-Receptor Negative Breast Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 109)

#	Related Disease	Score	Top Affiliating Genes
1	estrogen-receptor positive breast cancer	29.7	ERBB2 ESR1 FOXA1 PGR
2	breast cancer	28.2	AR BRCA1 EGF ERBB2 ESR1 FOXA1
3	vulvar syringoma	10.9	ESR1 PGR
4	lung leiomyoma	10.9	ESR1 PGR
5	vestibular gland benign neoplasm	10.9	ESR1 PGR
6	bartholin's gland adenoma	10.9	ESR1 PGR
7	vulvar benign neoplasm	10.8	ESR1 PGR
8	scirrhous adenocarcinoma	10.8	ERBB2 PGR
9	trigonitis	10.8	ESR1 PGR
10	breast apocrine carcinoma	10.8	ERBB2 PGR
11	vulvar leiomyoma	10.8	ESR1 PGR
12	comedo carcinoma	10.8	ERBB2 ESR1
13	predominantly cortical thymoma	10.8	ESR1 PGR
14	postmenopausal atrophic vaginitis	10.8	AR ESR1
15	breast mucoepidermoid carcinoma	10.8	ERBB2 PGR
16	breast metaplastic carcinoma	10.8	ERBB2 PGR
17	intracystic papillary adenoma	10.8	ERBB2 PGR
18	progesterone resistance	10.8	ESR1 PGR
19	progesterone-receptor negative breast cancer	10.8	ERBB2 PGR
20	cribriform carcinoma	10.8	ESR1 PGR
21	gastric signet ring cell adenocarcinoma	10.8	ESR1 PGR
22	endometrial mucinous adenocarcinoma	10.8	ESR1 PGR
23	sebaceous adenoma	10.8	EGF ESR1
24	adenoid basal cell carcinoma	10.8	ESR1 PGR
25	bartholin's gland benign neoplasm	10.7	ESR1 PGR
26	deep angioma	10.7	ESR1 PGR
27	calcifying aponeurotic fibroma	10.7	EGF PGR
28	corneal abscess	10.7	AR PGR
29	cervical carcinosarcoma	10.7	ESR1 PGR
30	uterine body mixed cancer	10.7	ERBB2 PGR
31	estrogen excess	10.7	ESR1 PGR
32	breast squamous cell carcinoma	10.7	ERBB2 PGR
33	intramuscular hemangioma	10.6	ESR1 PGR
34	mammographic density	10.6	ESR1 PGR
35	endometrial squamous cell carcinoma	10.6	AR ESR1 PGR
36	glassy cell carcinoma of the cervix	10.6	ERBB2 ESR1 PGR
37	gender identity disorder	10.6	AR ESR1 PGR
38	retinitis pigmentosa 47	10.6	ESR1 PGR
39	epispadias	10.6	EGF ERBB2
40	breast scirrhous carcinoma	10.6	ERBB2 ESR1 PGR
41	progesterone-receptor positive breast cancer	10.6	ERBB2 ESR1 PGR
42	microglandular adenosis	10.6	ERBB2 PGR
43	uterine corpus cancer	10.6	ERBB2 ESR1 PGR
44	paget disease, extramammary	10.6	AR ERBB2
45	breast benign neoplasm	10.6	ERBB2 ESR1 PGR
46	thoracic benign neoplasm	10.6	ERBB2 ESR1 PGR
47	inflammatory breast carcinoma	10.6	ERBB2 ESR1 PGR
48	mixed cell type cancer	10.6	ERBB2 ESR1 PGR
49	gynecomastia	10.6	AR ESR1 PGR
50	lipid-rich carcinoma	10.6	ERBB2 ESR1 PGR

Graphical network of the top 20 diseases related to Estrogen-Receptor Negative Breast Cancer:

Sources

Symptoms & Phenotypes for Estrogen-Receptor Negative Breast Cancer

MGI Mouse Phenotypes related to Estrogen-Receptor Negative Breast Cancer:

⁴⁶ (show all 12)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	growth/size/body region	MP:0005378	10.16	PTPRA WNT5A ETS1 FOXA1 ESR1 CCAR2
2	endocrine/exocrine gland	MP:0005379	10.13	WNT5A ETS1 FOXA1 PGR ESR1 EGF
3	homeostasis/metabolism	MP:0005376	10.13	PTPRA WNT5A ETS1 FOXA1 PGR BRCA1
4	immune system	MP:0005387	10.06	WNT5A ETS1 FOXA1 PGR ESR1 CCAR2
5	digestive/alimentary	MP:0005381	10.05	WNT5A FOXA1 ESR1 EGF AR ERBB2
6	embryo	MP:0005380	10.04	PGR WNT5A ETS1 BRCA1 ESR1 AR
7	integument	MP:0010771	9.97	ETS1 FOXA1 PGR ESR1 EGF AR
8	limbs/digits/tail	MP:0005371	9.8	WNT5A PGR ESR1 AR ERBB2 BRCA1
9	muscle	MP:0005369	9.73	PGR ESR1 WNT5A BRCA1 AR ERBB2
10	neoplasm	MP:0002006	9.7	FOXA1 PGR CCAR2 AR ERBB2 BRCA1
11	normal	MP:0002873	9.5	PGR WNT5A BRCA1 ESR1 EGF AR
12	reproductive system	MP:0005389	9.17	PGR ESR1 WNT5A BRCA1 EGF AR

Sources

Drugs & Therapeutics for Estrogen-Receptor Negative Breast Cancer

Drugs for Estrogen-Receptor Negative Breast Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 125)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Bevacizumab

Approved, Investigational

Phase 3,Phase 2,Not Applicable

216974-75-3

Cyclophosphamide

Approved, Investigational

Phase 3,Phase 2,Not Applicable

50-18-0, 6055-19-2

2907

Docetaxel

Approved, Investigational

Phase 3,Not Applicable

114977-28-5

148124

Epirubicin

Approved

Phase 3,Phase 2

56420-45-2

41867

Fluorouracil

Approved

Phase 3

51-21-8

3385

Progesterone

Approved, Vet_approved

Phase 3,Phase 2,Phase 1,Not Applicable

57-83-0

5994

Trastuzumab

Approved, Investigational

Phase 3,Phase 2

180288-69-1

9903

Carboplatin

Approved

Phase 2, Phase 3

41575-94-4

10339178 498142 38904

Gemcitabine

Approved

Phase 2, Phase 3

95058-81-4

60750

Paclitaxel

Approved, Vet_approved

Phase 2, Phase 3,Phase 3

33069-62-4

36314

Goserelin

Approved

Phase 3

65807-02-5

47725 5311128

Capecitabine

Approved, Investigational

Phase 3,Phase 2

154361-50-9

60953

Methotrexate

Approved

Phase 3,Phase 2

1959-05-2, 59-05-2

126941

Doxorubicin

Approved, Investigational

Phase 3,Phase 2

23214-92-8

31703

Lenograstim

Approved, Investigational

Phase 3,Phase 2

135968-09-1

Triamcinolone

Approved, Vet_approved

Phase 3

124-94-7

31307

Folic Acid

Approved, Nutraceutical, Vet_approved

Phase 3,Phase 2

59-30-3

6037

leucovorin

Approved, Nutraceutical

Phase 3,Phase 2

58-05-9

143 6006

Lapatinib

Approved March 2007, Investigational

Phase 3

231277-92-2, 388082-78-8

208908 9941095

Doxil

Approved June 1999

Phase 3,Phase 2

31703

Alkylating Agents

Phase 3,Phase 2,Phase 1,Not Applicable

Angiogenesis Inhibitors

Phase 3,Phase 2,Not Applicable

Angiogenesis Modulating Agents

Phase 3,Phase 2,Not Applicable

Anti-Bacterial Agents

Phase 3,Phase 2

Antibiotics, Antitubercular

Phase 3,Phase 2

Antimetabolites

Phase 3,Phase 2

Antimetabolites, Antineoplastic

Phase 3,Phase 2

Antineoplastic Agents, Alkylating

Phase 3,Phase 2,Phase 1,Not Applicable

Antirheumatic Agents

Phase 3,Phase 2,Not Applicable

Estrogens

Phase 3,Phase 2,Phase 1,Not Applicable

Hormone Antagonists

Phase 3,Phase 2,Phase 1,Not Applicable

Hormones

Phase 3,Phase 2,Phase 1,Not Applicable

Hormones, Hormone Substitutes, and Hormone Antagonists

Phase 3,Phase 2,Phase 1,Not Applicable

Immunosuppressive Agents

Phase 3,Phase 2,Not Applicable

Progestins

Phase 3,Phase 2,Phase 1,Not Applicable

Topoisomerase Inhibitors

Phase 3,Phase 2,Phase 1

Protein Kinase Inhibitors

Phase 3,Phase 2,Phase 1,Not Applicable

Albumin-Bound Paclitaxel

Phase 2, Phase 3,Phase 3

Anti-Infective Agents

Phase 2, Phase 3

Antimitotic Agents

Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable

Antineoplastic Agents, Phytogenic

Phase 2, Phase 3,Phase 3,Phase 1

Antiviral Agents

Phase 2, Phase 3

Antineoplastic Agents, Hormonal

Phase 3,Phase 2

Dermatologic Agents

Phase 3,Phase 2

Folic Acid Antagonists

Phase 3,Phase 2

Nucleic Acid Synthesis Inhibitors

Phase 3,Phase 2

Vitamin B Complex

Phase 3,Phase 2

triamcinolone acetonide

Phase 3

Triamcinolone diacetate

Phase 3

Triamcinolone hexacetonide

Phase 3

Interventional clinical trials:

(show all 50)

#	Name	Status	NCT ID	Phase	Drugs
1	Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Nonmetastatic Breast Cancer	Unknown status	NCT01093235	Phase 3	cyclophosphamide;docetaxel;epirubicin hydrochloride;fluorouracil
2	Trastuzumab or Lapatinib Ditosylate in Treating Women With Early Breast Cancer	Unknown status	NCT01104571	Phase 3	lapatinib ditosylate
3	Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer)	Completed	NCT01881230	Phase 2, Phase 3	nab-Paclitaxel;Carboplatin;Gemcitabine
4	Goserelin in Preventing Early Menopause in Premenopausal Women Undergoing Chemotherapy for Stage I, Stage II, or Stage III Breast Cancer	Completed	NCT00427245	Phase 3	cyclophosphamide;goserelin acetate
5	Combination Chemotherapy With or Without Capecitabine and/or Trastuzumab Before Surgery in Treating Women With Stage I, Stage II, or Stage III Breast Cancer	Completed	NCT00288002	Phase 3	capecitabine;cyclophosphamide;docetaxel;epirubicin hydrochloride
6	Low-dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-negative Early Breast Cancer	Completed	NCT00022516	Phase 3	Cyclophosphamide;Methotrexate
7	S0230 Goserelin in Preventing Ovarian Failure in Women Receiving Chemotherapy for Breast Cancer	Completed	NCT00068601	Phase 3	cyclophosphamide;goserelin acetate
8	MRI and Mammography Before Surgery in Patients With Stage I-II Breast Cancer	Recruiting	NCT01805076	Phase 3
9	Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer	Active, not recruiting	NCT01547741	Phase 3	Doxorubicin;Cyclophosphamide;Docetaxel;Paclitaxel
10	Higher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery	Active, not recruiting	NCT01349322	Phase 3
11	S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer	Active, not recruiting	NCT00070564	Phase 3	AC regimen;cyclophosphamide;doxorubicin hydrochloride;paclitaxel
12	PHASE II TRIAL OF THE CYCLIN-DEPEDENT KINASE INHIBITOR PD 0332991 IN PATIENTS WITH CANCER	Unknown status	NCT01037790	Phase 2	PD-0332991
13	Phase II Trial of Preoperative Therapy With Gefitinib and Chemotherapy in Patients With ERneg Breast Cancer	Completed	NCT00239343	Phase 2	gefitinib
14	Medroxyprogesterone +/- Cyclophosphamide & Methotrexate in Hormone Receptor-Negative Recurrent/Metastatic Breast Cancer	Completed	NCT00577122	Phase 2	Medroxyprogesterone progesterone acetate (MPA);Medroxyprogesterone with Cyclophosphamide + Methotrexate
15	Saracatinib in Treating Patients With Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed By Surgery	Completed	NCT00559507	Phase 2	saracatinib
16	Combination Chemotherapy and Filgrastim Before Surgery in Treating Patients With HER2-Positive Breast Cancer That Can Be Removed By Surgery	Completed	NCT00194779	Phase 2	doxorubicin hydrochloride;cyclophosphamide;paclitaxel;capecitabine;methotrexate;vinorelbine tartrate;tamoxifen citrate;letrozole
17	Combination Chemotherapy and Peripheral Blood Stem Cell Transplant Followed By Aldesleukin and Sargramostim in Treating Patients With Inflammatory Stage IIIB or Metastatic Stage IV Breast Cancer	Completed	NCT00003199	Phase 2	tamoxifen citrate;busulfan;thiotepa;melphalan
18	Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer	Completed	NCT01105312	Phase 1, Phase 2	letrozole;panobinostat
19	S0800, Nab-Paclitaxel, Doxorubicin, Cyclophosphamide, and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer	Completed	NCT00856492	Phase 2	cyclophosphamide;doxorubicin hydrochloride;paclitaxel albumin-stabilized nanoparticle formulation
20	Bendamustine and Erlotinib in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Breast Cancer	Completed	NCT00834678	Phase 1, Phase 2	bendamustine;erlotinib;Maintenance erlotinib
21	Doxorubicin and Cyclophosphamide in Treating Older Women With Stage I, Stage II, or Stage III Breast Cancer That Has Been Removed By Surgery	Completed	NCT00424203	Phase 2	AC regimen;cyclophosphamide;doxorubicin hydrochloride
22	Phase II Short-term Adjuvant Therapy and Biomarker Studies With Targeted Agents in Women With Estrogen Receptor Negative Breast Cancer	Recruiting	NCT01471106	Phase 2	Dasatinib
23	Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients With Triple Negative Stage II-III Breast Cancer	Recruiting	NCT02315196	Phase 2	pegylated liposomal doxorubicin hydrochloride;epirubicin hydrochloride;carboplatin;paclitaxel
24	Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca	Recruiting	NCT02957968	Phase 2	Doxorubicin;Cyclophosphamide;Paclitaxel;Carboplatin;Decitabine;Pembrolizumab
25	Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab Followed By Bevacizumab and Erlotinib Hydrochloride in Treating Patients With Metastatic Breast Cancer	Active, not recruiting	NCT00733408	Phase 2	paclitaxel albumin-stabilized nanoparticle formulation;erlotinib hydrochloride
26	Carboplatin and Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IIB-IIIC Breast Cancer	Active, not recruiting	NCT01818063	Phase 2	Paclitaxel;Carboplatin;Doxorubicin;Cyclophosphamide;Veliparib
27	Carboplatin and Eribulin Mesylate in Triple Negative Breast Cancer Patients	Active, not recruiting	NCT01372579	Phase 2	eribulin mesylate;carboplatin
28	Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Older Patients With Locally Advanced or Metastatic Breast Cancer	Active, not recruiting	NCT01463072	Phase 2	paclitaxel albumin-stabilized nanoparticle formulation
29	Targeted T Cells After Neoadjuvant Chemotherapy in Treating Women With Stage II or III Breast Cancer Undergoing Surgery	Active, not recruiting	NCT01147016	Phase 2	cyclophosphamide;doxorubicin hydrochloride;paclitaxel
30	GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer	Terminated	NCT01918306	Phase 1, Phase 2	cisplatin;GDC -0941
31	Entinostat and Anastrozole in Treating Postmenopausal Women With TNBC That Can Be Removed by Surgery	Terminated	NCT01234532	Phase 2	entinostat;anastrozole
32	RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer	Terminated	NCT01217411	Phase 1, Phase 2	Gamma-secretase/Notch signalling pathway inhibitor RO4929097
33	Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced, Metastatic, or Recurrent Triple Negative Invasive Breast Cancer	Terminated	NCT01151449	Phase 2	gamma-secretase/Notch signalling pathway inhibitor RO4929097
34	Breast-Conserving Surgery Followed by Radiation Therapy With MRI-Detected Stage I or Stage II Breast Cancer	Withdrawn	NCT01100489	Phase 2
35	Oral Microencapsulated Diindolylmethane in Treating Patients With Stage II-III Triple Negative, Androgen Receptor Positive Breast Cancer Who Have Undergone Chemotherapy and Surgery	Withdrawn	NCT01612910	Phase 2	oral microencapsulated diindolylmethane
36	Defined Green Tea Catechin Extract in Treating Women With Hormone Receptor Negative Stage I-III Breast Cancer	Completed	NCT00516243	Phase 1	defined green tea catechin extract
37	Veliparib, Cisplatin, and Vinorelbine Ditartrate in Treating Patients With Recurrent and/or Metastatic Breast Cancer	Completed	NCT01104259	Phase 1	veliparib;cisplatin;vinorelbine tartrate
38	7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)	Completed	NCT00031681	Phase 1	7-hydroxystaurosporine;irinotecan hydrochloride
39	Clinical Trial of Trametes Versicolor in Women With Breast Cancer	Completed	NCT00680667	Phase 1
40	Studying Changes in Breast Density in Patients With Early-Stage Breast Cancer Treated With Metformin Hydrochloride or Placebo on CAN-NCIC-MA.32	Unknown status	NCT01666171		metformin hydrochloride
41	Study of Tumor and Blood Samples From Women With Breast Cancer	Unknown status	NCT00897728
42	Study of Calgranulin A/B Levels in Patients With Newly Diagnosed Stage I,II,III Breast Cancer	Completed	NCT00900133
43	Studying Biopsy Samples in Women Undergoing First-Line Chemotherapy for Metastatic Breast Cancer	Completed	NCT00870168	Not Applicable	chemotherapy
44	TC Avastin. ICORG 08-10, V6	Completed	NCT00911716	Not Applicable	cyclophosphamide;docetaxel
45	Quality of Life, Employment, and Informal Care Costs in Women Who Are Receiving Chemotherapy for Breast Cancer	Completed	NCT00115505
46	Surgical Resection With or Without Axillary Lymph Node Dissection in Treating Women With Node-Negative Breast Cancer and Sentinel Lymph Node Micrometastases	Completed	NCT00072293	Not Applicable
47	Effects of Chemotherapy on the Brain in Women With Newly Diagnosed Early-Stage Breast Cancer	Completed	NCT00755313		aromatase inhibition therapy;carboplatin;cyclophosphamide;docetaxel;doxorubicin hydrochloride
48	Chemotherapy Decisions and Outcomes in Older Women With Newly Diagnosed Breast Cancer	Completed	NCT00068328
49	Assessment of Candidate Protein Expression in Breast Cancer Specimens	Recruiting	NCT00918892
50	Erlotinib in Treating Women Undergoing Surgery For Stage I, Stage II, or Stage III Breast Cancer	Terminated	NCT00503841	Not Applicable	erlotinib hydrochloride

Search NIH Clinical Center for Estrogen-Receptor Negative Breast Cancer

Sources

Genetic Tests for Estrogen-Receptor Negative Breast Cancer

Sources

Anatomical Context for Estrogen-Receptor Negative Breast Cancer

MalaCards organs/tissues related to Estrogen-Receptor Negative Breast Cancer:

⁴¹

Breast, Brain, Lymph Node, Bone, T Cells, Colon, Endothelial

Sources

Publications for Estrogen-Receptor Negative Breast Cancer

Articles related to Estrogen-Receptor Negative Breast Cancer:

(show top 50) (show all 185)

#	Title	Authors	Year
1	Analysis of the miRNA-mRNA-lncRNA network in human estrogen receptor-positive and estrogen receptor-negative breast cancer based on TCGA data. ( 29518546 )	Xiao B....Li L.	2018
2	Associations between Diet Quality Scores and Risk of Postmenopausal Estrogen Receptor-Negative Breast Cancer: A Systematic Review. ( 29378048 )	Du M....Fung T.T.	2018
3	Type II Diabetes and Incidence of Estrogen Receptor Negative Breast Cancer in African American Women. ( 29141994 )	Palmer J.R....Denis G.V.	2017
4	AGR2 associates with HER2 expression predicting poor outcome in subset of estrogen receptor negative breast cancer patients. ( 28238761 )	Ondrouskova E....Hrstka R.	2017
5	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. ( 29058716 )	Milne R.L....AlnA	2017
6	Overexpression of lipid metabolism genes and PBX1 in the contralateral breasts of women with estrogen receptor-negative breast cancer. ( 28263391 )	Wang J....Khan S.A.	2017
7	WP1130 increases cisplatin sensitivity through inhibition of usp9x in estrogen receptor-negative breast cancer cells. ( 28469783 )	Fu P....Zheng S.	2017
8	Coexpression of NOS2 and COX2 accelerates tumor growth and reduces survival in estrogen receptor-negative breast cancer. ( 29087320 )	Basudhar D....Wink D.A.	2017
9	PPARs as determinants of the estrogen receptor lineage: use of synthetic lethality for the treatment of estrogen receptor-negative breast cancer. ( 28881566 )	Glazer R.I....Kopelovich L.	2017
10	Toll-like receptor 4 as a predictor of clinical outcomes of estrogen receptor-negative breast cancer in Saudi women. ( 28280355 )	Semlali A....Alanazi M.S.	2017
11	Trans-ethnic predicted expression genome-wide association analysis identifies a gene for estrogen receptor-negative breast cancer. ( 28957356 )	Gao G....Huo D.	2017
12	Androgen Receptor Expression and Bicalutamide Antagonize Androgen Receptor Inhibit I^-Catenin Transcription Complex in Estrogen Receptor-Negative Breast Cancer. ( 29069648 )	Huang R....Panga D.	2017
13	Jim Crow and estrogen-receptor-negative breast cancer: US-born black and white non-Hispanic women, 1992-2012. ( 27988896 )	Krieger N....Waterman P.D.	2017
14	Targeting Aberrant p70S6K Activation for Estrogen Receptor Negative Breast Cancer Prevention. ( 28877935 )	Wang X....Yu D.	2017
15	Effect of 17I^-estradiol on estrogen receptor negative breast cancer cells in an osteolytic mouse model. ( 29133279 )	Cohen D.J....Schwartz Z.	2017
16	Impact of suppression of tumorigenicity 14 (ST14)/serine protease 14 (prss14) expression analysis on the prognosis and management of estrogen receptor negative breast cancer. ( 27167193 )	Kim S....Kim M.G.	2016
17	Is estrogen receptor negative breast cancer risk associated with a fast life history strategy? ( 26781544 )	Hidaka B.H....Boddy A.M.	2016
18	Plasma fluorescent oxidation products and risk of estrogen receptor-negative breast cancer in the Nurses' Health Study and Nurses' Health Study II. ( 27294610 )	Hirko K.A....Eliassen A.H.	2016
19	Benefit of adjuvant radiotherapy after breast-conserving therapy among elderly women with T1-T2N0 estrogen receptor-negative breast cancer. ( 27328114 )	Eaton B.R....Ward K.C.	2016
20	Prognostic significance of Claudin 12 in estrogen receptor-negative breast cancer. ( 26926102 )	Iravani O....Bay B.H.	2016
21	Genome-wide Association Studies in Women of African Ancestry Identified 3q26.21 as a Novel Susceptibility Locus for Estrogen Receptor Negative Breast Cancer. ( 27594435 )	Huo D....Haiman C.A.	2016
22	A novel curcumin derivative increases the cytotoxicity of raloxifene in estrogen receptor-negative breast cancer cell lines. ( 26648459 )	Taurin S....Rosengren R.J.	2016
23	Aromatase inhibitor-induced bone loss increases the progression of estrogen receptor-negative breast cancer in bone and exacerbates muscle weakness in vivo. ( 28039445 )	Wright L.E....Guise T.A.	2016
24	Estrogen stimulated migration and invasion of estrogen receptor-negative breast cancer cells involves an ezrin-dependent crosstalk between G protein-coupled receptor 30 and estrogen receptor beta signaling. ( 26850467 )	Zhou K....Wang T.	2016
25	The Circadian Rhythm Gene Arntl2 Is a Metastasis Susceptibility Gene for Estrogen Receptor-Negative Breast Cancer. ( 27656887 )	Ha N.H....Hunter K.W.	2016
26	Adjuvant Radiation Improves Survival in Older Women Following Breast-Conserving Surgery for Estrogen Receptor-Negative Breast Cancer. ( 27431462 )	Daugherty E.C....Shapiro A.	2016
27	Life history theory and breast cancer risk: methodological and theoretical challenges: Response to &quot;Is estrogen receptor negative breast cancer risk associated with a fast life history strategy?&quot;. ( 26874356 )	Aktipis A.	2016
28	Effect of sodium/iodide symporter (NIS)-mediated radioiodine therapy on estrogen receptor-negative breast cancer. ( 25955347 )	Yao C....Wang S.	2015
29	NADH-Cytochrome b5 Reductase 3 Promotes Colonization and Metastasis Formation and Is a Prognostic Marker of Disease-Free and Overall Survival in Estrogen Receptor-Negative Breast Cancer. ( 26351264 )	Lund R.R....LA	2015
30	Induction of apoptosis and oxidative stress in estrogen receptor-negative breast cancer, MDA-MB231 cells, by ethanolic mango seed extract. ( 25881293 )	Abdullah A.S....Al-Qubaisi M.S.	2015
31	Effective Targeting of Estrogen Receptor-Negative Breast Cancers with the Protein Kinase D Inhibitor CRT0066101. ( 25852060 )	Borges S....Storz P.	2015
32	Beyond immune density: critical role of spatial heterogeneity in estrogen receptor-negative breast cancer. ( 26621491 )	Nawaz S....Yuan Y.	2015
33	Important Role of Menarche in Development of Estrogen Receptor-Negative Breast Cancer in African American Women. ( 26085483 )	Ambrosone C.B....Palmer J.R.	2015
34	Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with prognosis of estrogen receptor-negative breast cancer after chemotherapy. ( 25849327 )	Lei J....AlnA	2015
35	Interleukin-8 upregulates integrin I^3 expression and promotes estrogen receptor-negative breast cancer cell invasion by activating the PI3K/Akt/NF-I_B pathway. ( 25979232 )	Shao N....Lin Y.	2015
36	Beyond immune density: critical role of spatial heterogeneity in estrogen receptor-negative breast cancer. ( 25720324 )	Nawaz S....Yuan Y.	2015
37	Nitric Oxide-Releasing Aspirin Suppresses NF-I_B Signaling in Estrogen Receptor Negative Breast Cancer Cells in Vitro and in Vivo. ( 26184135 )	Nath N....Kashfi K.	2015
38	N1-Guanyl-1,7-Diaminoheptane Sensitizes Estrogen Receptor Negative Breast Cancer Cells to Doxorubicin by Preventing Epithelial-Mesenchymal Transition through Inhibition of Eukaryotic Translation Initiation Factor 5A2 Activation. ( 26279450 )	Liu Y....Zheng S.	2015
39	Different anticancer effects of Saxifragifolin A on estrogen receptor-positive and estrogen receptor-negative breast cancer cells. ( 26220629 )	Kim K.H....Pyo S.	2015
40	Expression of sarcosine metabolism-related proteins in estrogen receptor negative breast cancer according to the androgen receptor and HER-2 status. ( 26339363 )	Kim M.J....Koo J.S.	2015
41	In Vitro and In Silico Evaluation of NF-I_B Targeted Costunolide Action on Estrogen Receptor-Negative Breast Cancer Cells-A Comparison with Normal Breast Cells. ( 24733523 )	Pitchai D....Banu S.	2014
42	Calcitriol restores antiestrogen responsiveness in estrogen receptor negative breast cancer cells: a potential new therapeutic approach. ( 24678876 )	Santos-MartA-nez N....GarcA-a-Becerra R.	2014
43	A positive role of DBC1 in PEA3-mediated progression of estrogen receptor-negative breast cancer. ( 25417701 )	Kim H.J....Kim J.H.	2014
44	Expression of autophagy-related proteins according to androgen receptor and HER-2 status in estrogen receptor-negative breast cancer. ( 25140630 )	Kim J.Y....Koo J.S.	2014
45	Advances in Preventive Therapy for Estrogen-Receptor-Negative Breast Cancer. ( 24829621 )	Litzenburger B.C....Brown P.H.	2014
46	A genome-wide &quot;pleiotropy scan&quot; does not identify new susceptibility loci for estrogen receptor negative breast cancer. ( 24523857 )	Campa D....Canzian F.	2014
47	Associations between estrogen receptor-negative breast cancer and timing of reproductive events differ between African American and European American women. ( 24718280 )	Ambrosone C.B....Bandera E.V.	2014
48	Expression of Reactive Oxygen Species-Related Proteins according to Androgen and HER-2 Status in Estrogen Receptor-Negative Breast Cancer. ( 25322848 )	Kim J.Y....Koo J.S.	2014
49	The prevalence of estrogen receptor-negative breast cancer in Ethiopia. ( 25433805 )	Kantelhardt E.J....Yonas B.	2014
50	Metabolic differences in estrogen receptor-negative breast cancer based on androgen receptor status. ( 24850180 )	Noh S....Koo J.S.	2014

Sources

Genes for Estrogen-Receptor Negative Breast Cancer

Genes related to Estrogen-Receptor Negative Breast Cancer (0 elite genes):

(show all 14)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	ESR1	Estrogen Receptor 1	Protein Coding	25.38	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
2	AR	Androgen Receptor	Protein Coding	22.57	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
3	ERBB2	Erb-B2 Receptor Tyrosine Kinase 2	Protein Coding	22.48	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
4	PGR	Progesterone Receptor	Protein Coding	22.24	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
5	PTPRA	Protein Tyrosine Phosphatase, Receptor Type A	Protein Coding	21.69	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
6	WNT5A	Wnt Family Member 5A	Protein Coding	21.42	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
7	CYB5R3	Cytochrome B5 Reductase 3	Protein Coding	21.3	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
8	CCAR2	Cell Cycle And Apoptosis Regulator 2	Protein Coding	21.24	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
9	CXCL8	C-X-C Motif Chemokine Ligand 8	Protein Coding	21.11	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
10	BRCA1	BRCA1, DNA Repair Associated	Protein Coding	20.91	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
11	CLPTM1L	CLPTM1 Like	Protein Coding	20.9	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
12	FOXA1	Forkhead Box A1	Protein Coding	20.86	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
13	EGF	Epidermal Growth Factor	Protein Coding	20.83	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
14	ETS1	ETS Proto-Oncogene 1, Transcription Factor	Protein Coding	20.82	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)

Sources

Variations for Estrogen-Receptor Negative Breast Cancer

Sources

Expression for Estrogen-Receptor Negative Breast Cancer

Search GEO for disease gene expression data for Estrogen-Receptor Negative Breast Cancer.

Sources

Pathways for Estrogen-Receptor Negative Breast Cancer

Pathways related to Estrogen-Receptor Negative Breast Cancer according to GeneCards Suite gene sharing:

(show all 11)

#	Super pathways	Score	Top Affiliating Genes
1	Glioma ³⁷ Show member pathways EGFR tyrosine kinase inhibitor resistance ³⁷ Endocrine resistance ³⁷ Melanoma ³⁷ Non-small cell lung cancer ³⁷ Signaling Pathways in Glioblastoma ¹	12.47	BRCA1 EGF ERBB2 ESR1
2	Gastric cancer ³⁷ Show member pathways Breast cancer ³⁷ Hepatocellular carcinoma ³⁷	12.3	BRCA1 EGF ERBB2 ESR1 PGR WNT5A
3	Pathways in cancer ³⁷	11.89	AR CXCL8 EGF ERBB2 ESR1 ETS1
4	Integrated Breast Cancer Pathway ¹	11.84	AR BRCA1 ESR1
5	Transcription Androgen Receptor nuclear signaling ²² Show member pathways Translation Non-genomic (rapid) action of Androgen Receptor ²²	11.79	AR EGF ERBB2 WNT5A
6	Embryonic and Induced Pluripotent Stem Cell Differentiation Pathways and Lineage-specific Markers ⁶⁵	11.76	EGF FOXA1 WNT5A
7	Signaling by ERBB4 ⁶⁶ Show member pathways Downregulation of ERBB4 signaling ⁶⁶ ErbB4 signaling events ¹ Nuclear signaling by ERBB4 ⁶⁶	11.59	EGF ERBB2 ESR1 PGR
8	Nuclear Receptor transcription pathway ⁶⁶ Show member pathways Nuclear Receptors ¹	11.56	AR ESR1 PGR
9	Bladder cancer ³⁷ ¹	11.44	CXCL8 EGF ERBB2
10	Validated targets of C-MYC transcriptional repression ¹	11.33	BRCA1 ERBB2 WNT5A
11	FOXA1 transcription factor network ¹ Show member pathways FOXA transcription factor networks ¹	10.92	AR BRCA1 ESR1 FOXA1

Sources

GO Terms for Estrogen-Receptor Negative Breast Cancer

Biological processes related to Estrogen-Receptor Negative Breast Cancer according to GeneCards Suite gene sharing:

(show all 25)

#	Name	GO ID	Score	Top Affiliating Genes
1	positive regulation of transcription by RNA polymerase II	GO:0045944	9.87	AR BRCA1 ESR1 ETS1 FOXA1 PGR
2	positive regulation of protein kinase B signaling	GO:0051897	9.8	EGF ERBB2 ESR1
3	positive regulation of canonical Wnt signaling pathway	GO:0090263	9.79	CCAR2 EGF WNT5A
4	male gonad development	GO:0008584	9.76	AR ESR1 WNT5A
5	phosphatidylinositol phosphorylation	GO:0046854	9.75	EGF ERBB2 ESR1
6	response to estradiol	GO:0032355	9.73	ESR1 ETS1 FOXA1
7	positive regulation of transcription, DNA-templated	GO:0045893	9.73	AR BRCA1 EGF ESR1 ETS1 WNT5A
8	positive regulation of angiogenesis	GO:0045766	9.67	BRCA1 CXCL8 ETS1 WNT5A
9	steroid hormone mediated signaling pathway	GO:0043401	9.63	AR ESR1 PGR
10	dopaminergic neuron differentiation	GO:0071542	9.62	FOXA1 WNT5A
11	uterus development	GO:0060065	9.6	ESR1 WNT5A
12	negative regulation of ERBB signaling pathway	GO:1901185	9.59	EGF ERBB2
13	positive regulation of intracellular estrogen receptor signaling pathway	GO:0033148	9.55	AR FOXA1
14	positive regulation of transcription by RNA polymerase III	GO:0045945	9.54	AR ERBB2
15	vagina development	GO:0060068	9.52	ESR1 WNT5A
16	prostate gland epithelium morphogenesis	GO:0060740	9.49	AR FOXA1
17	positive regulation of cell-cell adhesion mediated by cadherin	GO:2000049	9.48	FOXA1 WNT5A
18	epithelial cell proliferation involved in mammary gland duct elongation	GO:0060750	9.43	ESR1 WNT5A
19	tertiary branching involved in mammary gland duct morphogenesis	GO:0060748	9.4	AR PGR
20	lateral sprouting involved in mammary gland duct morphogenesis	GO:0060599	9.16	AR WNT5A
21	mammary gland alveolus development	GO:0060749	9.13	AR EGF ESR1
22	positive regulation of gene expression	GO:0010628	9.1	AR BRCA1 EGF ERBB2 ETS1 WNT5A
23	regulation of transcription, DNA-templated	GO:0006355	10.17	AR BRCA1 CCAR2 ERBB2 ESR1 ETS1
24	transcription, DNA-templated	GO:0006351	10.11	AR BRCA1 CCAR2 ERBB2 ESR1 ETS1
25	regulation of transcription by RNA polymerase II	GO:0006357	10.08	AR BRCA1 ERBB2 ESR1 ETS1 FOXA1

Molecular functions related to Estrogen-Receptor Negative Breast Cancer according to GeneCards Suite gene sharing:

(show all 14)

#	Name	GO ID	Score	Top Affiliating Genes
1	DNA binding transcription factor activity	GO:0003700	9.93	AR ESR1 ETS1 FOXA1 PGR WNT5A
2	sequence-specific DNA binding	GO:0043565	9.88	AR ESR1 ETS1 FOXA1 PGR
3	RNA polymerase II proximal promoter sequence-specific DNA binding	GO:0000978	9.83	AR ESR1 ETS1 PGR
4	transcription factor binding	GO:0008134	9.8	AR ESR1 ETS1 FOXA1
5	transcription regulatory region DNA binding	GO:0044212	9.71	AR BRCA1 FOXA1 WNT5A
6	Ras guanyl-nucleotide exchange factor activity	GO:0005088	9.69	EGF ERBB2 PTPRA
7	ATPase binding	GO:0051117	9.61	AR ESR1 PGR
8	enzyme binding	GO:0019899	9.55	AR BRCA1 CCAR2 ESR1 PGR
9	phosphatidylinositol-4,5-bisphosphate 3-kinase activity	GO:0046934	9.54	EGF ERBB2 ESR1
10	steroid hormone receptor activity	GO:0003707	9.5	AR ESR1 PGR
11	nuclear receptor activity	GO:0004879	9.43	AR ESR1 PGR
12	steroid binding	GO:0005496	9.13	AR ESR1 PGR
13	transcriptional activator activity, RNA polymerase II proximal promoter sequence-specific DNA binding	GO:0001077	9.02	AR ESR1 ETS1 FOXA1 PGR
14	protein binding	GO:0005515	10.35	AR BRCA1 CCAR2 CXCL8 CYB5R3 EGF

Sources

Sources for Estrogen-Receptor Negative Breast Cancer

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ ExPASy

¹⁸ FDA Approved Drugs

¹⁹ FMA

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ Genetics Home Reference

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HGMD

³¹ HMDB

³² HPO

³³ ICD10

³⁴ ICD10 via Orphanet

³⁵ ICD9CM

³⁶ IUPHAR

³⁷ KEGG

³⁸ LifeMap

³⁹ LncRNADisease

⁴⁰ LOVD

⁴¹ MalaCards

⁴² MedGen

⁴³ MedlinePlus

⁴⁴ MeSH

⁴⁵ MESH via Orphanet

⁴⁶ MGI

⁴⁷ miR2Disease

⁴⁸ NCBI Bookshelf

⁴⁹ NCI

⁵⁰ NCIt

⁵¹ NDF-RT

⁵² NIH Clinical Center

⁵³ NIH Rare Diseases

⁵⁴ NINDS

⁵⁵ Novoseek

⁵⁶ Novus Biologicals

⁵⁷ OMIM

⁵⁸ OMIM via Orphanet

⁵⁹ Orphanet

⁶⁰ PathCards

⁶¹ PharmGKB

⁶² PubMed

⁶³ PubMed Health

⁶⁴ QIAGEN

⁶⁵ R&D Systems

⁶⁶ Reactome

⁶⁷ Sino Biological

⁶⁸ SNOMED-CT

⁶⁹ SNOMED-CT via HPO

⁷⁰ SNOMED-CT via Orphanet

⁷¹ TGDB

⁷² Tocris

⁷³ UMLS

⁷⁴ UMLS via Orphanet

⁷⁵ UniProtKB/Swiss-Prot

⁷⁶ Wikipedia